Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Melanoma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Imatinib Mesylate 10Sunitinib 4spartalizumab 2pembrolizumab 2nilotinib 2Surveys and Questionnaires 2tanespimycin 1ribociclib 1pexidartinib 1pazopanib 1olaratumab 1oblimersen 1motexafin lutetium 1masitinib 1guadecitabine 1ferric carboxymaltose 1famitinib 1epacadostat 1Surgical Procedures, Operative 1Quality of Life 1Observation 1Iron-Dextran Complex 1Indocyanine Green 1Immunoglobulin G 1Fluorescein 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Gastrointestinal Stromal Tumors × pexidartinib × Clear all
NCT02452424 2020-03-05

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Daiichi Sankyo

Phase 1/2 Terminated
78 enrolled 19 charts
DermatologicGastrointestinalGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡